About hiss

This author has not yet filled in any details.
So far hiss has created 167 blog entries.
3 August, 2023

Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control

2023-09-21T14:44:33+03:00By |Categories: Publications|Tags: , |

Evangelos J. Giamarellos-Bourboulis on behalf of the European Sepsis Alliance (ESA), Annelies S. Zinkernagel on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Edoardo De Robertis on behalf of the European Society of Anesthesiology and Intensive Care (ESAIC), Élie Azoulay on behalf of the European Society for Intensive Care Medicine

7 July, 2023

Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes

2023-07-07T09:39:43+03:00By |Categories: Biomarkers, Publications|Tags: , |

  Nick Keur, Maria Saridaki, Isis Ricano-Ponce, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis, Vinod Kumar Respiratory Medicine 2023 Jun 25; 217:107331 DOI: 10.1016/j.rmed.2023.107331Download pdf 🡇 Funding   This work was funded by the ZonMw (10430012010002) to VK. The SAVE study was funded by the Hellenic Institute for the Study of Sepsis, Swedish Orphan

9 March, 2023

Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID‑19

2023-03-09T12:07:30+03:00By |Categories: Biomarkers, Publications|Tags: |

 Evdoxia Kyriazopoulou, Konstantinos Leventogiannis, Georgios Tavoulareas, Efstratios Mainas, Konstantinos Toutouzas, Christos Mathas, Athanassios Prekates, Vissaria Sakka, Periklis Panagopoulos, Konstantinos Syrigos & Evangelos J. Giamarellos-Bourboulis Scientific Reports 13, Article number: 3814 (2023) DOI: 10.1038/s41598-023-30807-5Download pdf 🡇 Funding  The study was funded in part by the FrameWork 7 project HemoSpec (Grant 611682) and in part

15 February, 2023

MODIFY

2024-01-03T17:02:26+03:00By |Categories: Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial) Brief Description The aim of the study is to demonstrate if using a combined strategy of rapid molecular diagnosis with BioFire® FilmArray® Blood Culture Identification 2 Panel and

10 February, 2023

Case report: The devil was hidden in the mastocytes – an unusually fulminant case of indolent systemic mastocytosis in a 45-year-old patient, missed for almost 20 years

2023-02-16T12:24:58+03:00By |Categories: Epidemiology, Publications|

Aristeidis E. Boukouris, Ioannis Michelakis, Dionysios Metaxas, Gianna Karapati, George Kanellis, Athina Lioni, Vasiliki Tzavara Frontiers Immunology, 14:1134587 DOI: 10.1111/cea.12318Download pdf 🡇 Funding This study was funded by the Hellenic Institute for the Study of Sepsis. Keywords: Case report

1 February, 2023

HDM-FUN-Candidemia

2024-01-03T16:56:31+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia: The HDM-FUN-Candidemia trial Brief Description Invasive fungal infections are an important cause of morbidity and mortality and lead to numerous hospital and ICU admissions. Candidemia is associated with a suppressed immune status

10 January, 2023

SAVE-LONG

2023-05-22T14:50:00+03:00By |Categories: Non-Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Symptom-guided Anakinra treatment for the Validation of immunE dysfunction persisting for LONG after hospital discharge for COVID-19 (SAVE-LONG) Brief Description SAVE-LONG is a call to the development of diagnostic tools and therapeutic modalities for patients with Long-COVID Syndrome. Details Status: ongoing Study Type: Non-interventional Study phase: II &

27 December, 2022

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial

2024-04-03T12:43:50+03:00By |Categories: Publications, Therapeutics|Tags: , , , |

Karolina Akinosoglou, Antigone Kotsaki, Ioanna-Maria Gounaridi, Eirini Christaki, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Massimo Fantoni, Aggeliki Rapti, Ioannis Kalomenidis, Georgios Chrysos, Gloria Boni, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vassiliki Tzavara, Asimina Safarika, Sofia Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios

27 December, 2022

Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: The AIDA open label, randomized, controlled Phase 4 trial

2024-04-03T12:38:22+03:00By |Categories: Publications, Therapeutics|Tags: , |

Antigone Kotsaki, Nikolaos Tziolos, Theano Kontopoulou, Ioannis M. Koutelidakis, Styliani Symbardi, Vaughan Reed, Miriam O’Hare, Zoi Alexiou, Helen Sambatakou, Konstantinos Toutouzas, Karolina Akinosoglou, Malvina Lada, Evangelos J. Giamarellos-Bourboulis, and Alasdair MacGowan eClinicalMedicine Volume 56, 101790, February 01, 2023 DOI: 10.1016/j.eclinm.2022.101790Download pdf 🡇 Funding The EU Seventh Research Framework Programme. Keywords: Minocycline; Rifampicin;

21 December, 2022

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol

2024-04-02T18:40:49+03:00By |Categories: Publications, Therapeutics|Tags: , , |

Antigone Kotsaki, Peter Pickkers , Michael Bauer, Thierry Calandra, Mihaela Lupse, W Joost Wiersinga, Sylvain Meylan , Frank Bloos, Tom van der Poll, Marleen A Slim , Niels van Mourik, Marcella C A Müller, Lonneke van Vught,8 Alexander P J Vlaar, Aline de Nooijer, Lieke Bakkerus, Sebastian Weis, Nikolaos Antonakos, Mihai G Netea, Evangelos

Go to Top